Viral vector-mediated gene transfer for CNS disease

Bibliography

• Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171(4356):737-8
   PubMed Web of Science ®Google Scholar
• Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972;175(25):949-55
   PubMedGoogle Scholar
• Morrow JF. The prospects for gene therapy in humans. Ann NY Acad Sci 1976;265:13-21
   PubMed Web of Science ®Google Scholar
• Aposhian HV. The use of DNA for gene therapy–the need, experimental approach, and implications. Perspect Biol Med 1970;14(1):98-108
   PubMed Web of Science ®Google Scholar
• Blaese RM, Culver KW, Miller AD, T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995;270(5235):475-80
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288(5466):669-72
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-9
   PubMed Web of Science ®Google Scholar
• Gene Therapy Clinical Trials Worldwide. John Wiley and Sons Ltd., 2007, Available from: http://www.wiley.co.uk/genetherapy/clinical. [Last accessed 1 December 2010]
   Google Scholar
• Friedmann T. The future for gene therapy–a reevaluation. Ann NY Acad Sci 1976;265:141-52
   PubMed Web of Science ®Google Scholar
• Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy–what have we learned? J Neurooncol 2003;65(3):227-36
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Leroux-Carlucci MA, Sion CJ, Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther 2009;16(6):805-14
   PubMed Web of Science ®Google Scholar
• Azzouz M, Martin-Rendon E, Barber RD, Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002;22(23):10302-12
   PubMed Web of Science ®Google Scholar
• Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009;4(4):495-505
   PubMed Web of Science ®Google Scholar
• Valori CF, Ning K, Wyles M, Azzouz M. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr Gene Ther 2008;8(6):406-18
   PubMed Web of Science ®Google Scholar
• Lundberg C, Bjorklund T, Carlsson T, Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008;8(6):461-73
   PubMed Web of Science ®Google Scholar
• Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005;5(4):387-98
   PubMed Web of Science ®Google Scholar
• Azzouz M, Le T, Ralph GS, Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004;114(12):1726-31
   PubMed Web of Science ®Google Scholar
• Tanase K, Teng Q, Krishnaney AA, Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004;1(1):128-36
   PubMed Web of Science ®Google Scholar
• Consiglio A, Gritti A, Dolcetta D, Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc Natl Acad Sci USA 2004;101(41):14835-40
   PubMed Web of Science ®Google Scholar
• Capowski EE, Schneider BL, Ebert AD, Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 2007;163(2):338-49
   PubMed Web of Science ®Google Scholar
• Harrow S, Papanastassiou V, Harland J, HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004;11(22):1648-58
   PubMed Web of Science ®Google Scholar
• Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 2009;16(4):455-60
   PubMed Web of Science ®Google Scholar
• Fraefel C. Gene delivery using helper virus-free HSV-1 amplicon vectors. Curr Protoc Neurosci 2007 Jul; Chapter 4:Unit 4 14
   Google Scholar
• Asadi-Moghaddam K, Chiocca EA. Prodrug-activation gene therapy. In: Kaplitt MG, During MJ, editors, Gene therapy in the central nervous system: from bench to bedside. San Diego, CA: Elsevier, Inc; 2006. p. 291-302
   Google Scholar
• Thomas CE, Schiedner G, Kochanek S, Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000;97(13):7482-7
   PubMed Web of Science ®Google Scholar
• Barcia C, Jimenez-Dalmaroni M, Kroeger KM, One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 2007;15(12):2154-63
   PubMed Web of Science ®Google Scholar
• Nandi S, Lesniak MS. Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther 2009;9(6):737-47
   PubMed Web of Science ®Google Scholar
• Immonen A, Vapalahti M, Tyynela K, AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10(5):967-72
   PubMed Web of Science ®Google Scholar
• Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004;11(Suppl 1):S10-7
   PubMed Web of Science ®Google Scholar
• Haberman RP, Samulski RJ, McCown TJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 2003;9(8):1076-80
   PubMed Web of Science ®Google Scholar
• Guy J, Qi X, Muzyczka N, Hauswirth WW. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol 1999;117(7):929-37
   PubMed Web of Science ®Google Scholar
• Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14(3):316-27
   PubMed Web of Science ®Google Scholar
• McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2005;5(3):333-8
   PubMed Web of Science ®Google Scholar
• Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008;15(11):858-63
   PubMed Web of Science ®Google Scholar
• Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 1998;9(8):1181-6
   PubMed Web of Science ®Google Scholar
• McFarland NR, Lee JS, Hyman BT, McLean PJ. Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 2009;109(3):838-45
   PubMed Web of Science ®Google Scholar
• Liu G, Martins IH, Chiorini JA, Davidson BL. Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther 2005;12(20):1503-8
   PubMed Web of Science ®Google Scholar
• Tenenbaum L, Chtarto A, Lehtonen E, Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 2004;6(Suppl 1):S212-22
   PubMed Web of Science ®Google Scholar
• Davidson BL, Stein CS, Heth JA, Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000;97(7):3428-32
   PubMed Web of Science ®Google Scholar
• Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008;16(6):1018-25
   PubMed Web of Science ®Google Scholar
• Duque S, Joussemet B, Riviere C, Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009;17(7):1187-96
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27(1):59-65
   PubMed Web of Science ®Google Scholar
• Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006;138(2):501-10
   PubMed Web of Science ®Google Scholar
• Burger C, Gorbatyuk OS, Velardo MJ, Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10(2):302-17
   PubMed Web of Science ®Google Scholar
• Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006;24(2):198-204
   PubMed Web of Science ®Google Scholar
• Li W, Asokan A, Wu Z, Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008;16(7):1252-60
   PubMed Web of Science ®Google Scholar
• Shevtsova Z, Malik JM, Michel U, Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 2005;90(1):53-9
   PubMed Web of Science ®Google Scholar
• Eberling JL, Jagust WJ, Christine CW, Results from a phase I safety trial of hAADC gene therapy for parkinson disease. Neurology 2008;70(21):1980-3
   PubMed Web of Science ®Google Scholar
• Federici T, Riley J, Park J, Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord. Clin Transl Sci 2009;2(2):165-7
   PubMed Web of Science ®Google Scholar
• Riley J, Butler J, Park J, Targeted spinal cord therapeutics delivery: stabilized platform and MER guidance validation. Stereotact Funct Neurosurg 2007;86(2):67-74
   PubMed Web of Science ®Google Scholar
• Riley J, Federici T, Park J, Cervical spinal cord therapeutics delivery: preclinical safety validation of a stabilized microinjection platform. Neurosurgery; 65(4):754-61; discussion 761-2
   PubMed Web of Science ®Google Scholar
• Kordower JH, Herzog CD, Dass B, Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60(6):706-15
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Holden JE, Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22(8):1124-32
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Gasmi M, Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 2008;16(10):1737-44
   PubMed Web of Science ®Google Scholar
• Towne C, Schneider BL, Kieran D, Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 2009: published online3 September 2009; doi: 10.1038/gt.2009.119
   Google Scholar
• Boulis NM, Noordmans AJ, Song DK, Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiol Dis 2003;14(3):535-41
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Llado J, Sherkat N, Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301(5634):839-42
   PubMed Web of Science ®Google Scholar
• Hollis ER, 2nd, Kadoya K, Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 2008;16(2):296-301
   PubMed Web of Science ®Google Scholar
• Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006;13(3):528-37
   PubMed Web of Science ®Google Scholar
• Mata M, Chattopadhyay M, Fink DJ. Gene therapy for the treatment of sensory neuropathy. Expert Opin Biol Ther 2006;6(5):499-507
   PubMed Web of Science ®Google Scholar
• Azzouz M, Ralph GS, Storkebaum E, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429(6990):413-7
   PubMed Web of Science ®Google Scholar
• Storek B, Harder NM, Banck MS, Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain 2006;2:4. Published online 30 January 2006, doi: 10.1186/1744-8069-2-4
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Watanabe A, Yamamoto M, Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med 2009;11(6):498-505
   PubMed Web of Science ®Google Scholar
• Towne C, Pertin M, Beggah AT, Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 2009;5:52. Published online 8 September 2009, doi: 10.1186/1744-8069-5-52
   PubMed Web of Science ®Google Scholar
• Storek B, Reinhardt M, Wang C, Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci USA 2008;105(3):1055-60
   PubMed Web of Science ®Google Scholar
• Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999;10(7):1251-7
   PubMed Web of Science ®Google Scholar
• Poliani PL, Brok H, Furlan R, Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001;12(8):905-20
   PubMed Web of Science ®Google Scholar
• Fedorova E, Battini L, Prakash-Cheng A, Lentiviral gene delivery to CNS by spinal intrathecal administration to neonatal mice. J Gene Med 2006;8(4):414-24
   PubMed Web of Science ®Google Scholar
• McCarty DM, Dirosario J, Gulaid K, Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009;16(11):1340-52
   PubMed Web of Science ®Google Scholar
• Leone P, Janson CG, Bilaniuk L, Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for canavan disease. Ann Neurol 2000;48(1):27-38
   PubMed Web of Science ®Google Scholar
• Janson C, McPhee S, Bilaniuk L, Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002;13(11):1391-412
   PubMed Web of Science ®Google Scholar
• McPhee SW, Janson CG, Li C, Immune responses to AAV in a phase I study for canavan disease. J Gene Med 2006;8(5):577-88
   PubMed Web of Science ®Google Scholar
• Hackett NR, Redmond DE, Sondhi D, Safety of direct administration of AAV2CUhCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum Gene Ther 2005;16(12):1484-503
   PubMed Web of Science ®Google Scholar
• Worgall S, Sondhi D, Hackett NR, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19(5):463-74
   PubMed Web of Science ®Google Scholar
• Sondhi D, Peterson DA, Edelstein AM, Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp Neurol 2008;213(1):18-27
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for parkinson's disease: an open label, phase I trial. Lancet 2007;369(9579):2097-105
   PubMed Web of Science ®Google Scholar
• Feigin A, Kaplitt MG, Tang C, Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007;104(49):19559-64
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Forsayeth J, Eberling JL, Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006;14(4):564-70
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS, Safety and tolerability of putaminal AADC gene therapy for parkinson disease. Neurology 2009;73(18):1662-9
   PubMedGoogle Scholar
• Marks WJ Jr., Ostrem JL, Verhagen L, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7(5):400-8
   PubMed Web of Science ®Google Scholar
• Siffert J, Marks WJ Jr, Starr PA, AAV2-neurturin (CERE-120) for advanced parkinson's disease (PD): efficacy and safety results from a controlled Phase 2 clinical trial. Soc Neurosci 2009; Chicago, IL; 2009
   Google Scholar
• Tuszynski MH, Thal L, Pay M, A phase 1 clinical trial of nerve growth factor gene therapy for alzheimer disease. Nat Med 2005;11(5):551-5
   PubMed Web of Science ®Google Scholar
• Nagahara AH, Bernot T, Moseanko R, Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009;215(1):153-9
   PubMed Web of Science ®Google Scholar
• Bishop KM, Hofer EK, Mehta A, Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 2008;211(2):574-84
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN, Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21(13):2508-18
   PubMed Web of Science ®Google Scholar
• Eck SL, Alavi JB, Alavi A, Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996;7(12):1465-82
   PubMed Web of Science ®Google Scholar
• Trask TW, Trask RP, Aguilar-Cordova E, Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1(2):195-203
   PubMed Web of Science ®Google Scholar
• Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003;65(3):279-89
   PubMed Web of Science ®Google Scholar
• Osborne R. Ark floats gene therapy's boat, for now. Nat Biotechnol 2008;26(10):1057-9
   PubMed Web of Science ®Google Scholar
• Langford G, Dayan A, Yla-Herttuala S, Eckland D. A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (cerepro) after intracerebral administration. J Gene Med 2009;11(6):468-76
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Smith KM, McKinney B, A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008;16(3):618-26
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, McBride JL, Herzog CD, Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of huntington's disease. Neurobiol Dis 2007;26(2):375-84
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, McBride JL, Han I, Intrastriatal CERE-120 (AAV-neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of huntington's disease. Neurobiol Dis 2009;34(1):40-50
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, RNA interference improves motor and neuropathological abnormalities in a huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102(16):5820-5
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Forsayeth J, Mirek H, Transduction of non-human primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 2009;20:225-37
   PubMed Web of Science ®Google Scholar
• Richichi C, Lin EJ, Stefanin D, Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004;24(12):3051-9
   PubMed Web of Science ®Google Scholar
• McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 2006;14(1):63-8
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Mayatepek E. Neurological manifestations in lysosomal storage disorders – from pathology to first therapeutic possibilities. Neuropediatrics 2005;36(5):285-9
   PubMed Web of Science ®Google Scholar
• Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 2008;97(457):22-7
   PubMedGoogle Scholar
• Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 2009;50(2):112-21
   PubMed Web of Science ®Google Scholar
• Fraldi A, Hemsley K, Crawley A, Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 2007;16(22):2693-702
   PubMed Web of Science ®Google Scholar
• Karolewski BA, Wolfe JH. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther 2006;14(1):14-24
   PubMed Web of Science ®Google Scholar
• Liu G, Martins I, Wemmie JA, Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005;25(41):9321-7
   PubMed Web of Science ®Google Scholar
• Federici T, Boulis N. Gene-based treatment of motor neuron diseases. Muscle Nerve 2006;33(3):302-23
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Day DM, Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11(4):429-33
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11(4):423-8
   PubMed Web of Science ®Google Scholar